Circulating PCSK9 and Risk of Myocardial Infarction

• Main Authors: Lars E. Laugsand, MD, PhD, Bjørn O. Åsvold, MD, PhD, Lars J. Vatten, MD, PhD, Imre Janszky, MD, PhD, Carl G. Platou, MD, Annika E. Michelsen, PhD, Jan K. Damås, MD, PhD, Pål Aukrust, MD, PhD, Thor Ueland, PhD
• Format: Article
• Language: English
• Published: Elsevier 2016-12-01
• Series: JACC: Basic to Translational Science
• Subjects: PCSK9 inflammation; epidemiology; myocardial infarction; prospective study; risk factors
• Online Access: http://www.sciencedirect.com/science/article/pii/S2452302X16300997
• ISSN: 2452-302X

The usefulness of circulating proprotein convertase subtilisin-kexin type 9 (PCSK9) as a risk marker of coronary heart disease in the general population remains unclear. In a nested case-control study in Norway, 1,488 incident myocardial infarctions were registered during 11.3 years of follow-up and compared with 3,819 controls. Compared with participants in the lowest quartile of PCSK9, myocardial infarction risk was 47% higher in the highest quartile after adjustment for age and sex. After additional adjustment for low-density lipoprotein cholesterol, the association was strongly attenuated. Thus, circulating PCSK9 does not contribute useful information in the assessment of myocardial infarction risk in the general population beyond the information provided by lipid measurements.